A Review of Proposals to Reform the Regulation of Complementary Medicines

In 2003, the Therapeutic Goods Administration instituted a major recall of products made by Pan Pharmaceuticals Limited. Later that year, an expert committee produced 49 recommendations for complementary medicines reform, many of which were to be implemented by the proposed Australia New Zealand The...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Australian health review 2009-05, Vol.33 (2), p.279-287
1. Verfasser: Harvey, Ken J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 287
container_issue 2
container_start_page 279
container_title Australian health review
container_volume 33
creator Harvey, Ken J
description In 2003, the Therapeutic Goods Administration instituted a major recall of products made by Pan Pharmaceuticals Limited. Later that year, an expert committee produced 49 recommendations for complementary medicines reform, many of which were to be implemented by the proposed Australia New Zealand Therapeutic Products Authority (ANZTPA). In 2008, the Pan Pharmaceuticals affair reached some conclusion in the courts, the ANZTPA had been abandoned and the case for reform had intensified. There was widespread and increasing use of complementary medicines yet consumers were often unaware that, unlike conventional medicines, these medicines were not evaluated for efficacy. The justification of this two-tiered regulatory system was that complementary medicines are relatively low-risk products. However low risk does not mean no risk. A number of consumers have been shown to use these products for conditions where there is no evidence of effect, potentially placing them at risk. In addition, promotion often overstates their benefits while minimising and sometimes denying known adverse effects and drug interactions. Complaint procedures are overloaded and the 'sanctions' available do not deter repeat offenders. A number of regulatory reforms have been suggested to overcome these problems; they are reviewed in this paper.
doi_str_mv 10.1071/AH090279
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_19563316</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><informt_id>10.3316/ielapa.161461363756458</informt_id><sourcerecordid>733361659</sourcerecordid><originalsourceid>FETCH-LOGICAL-c576t-f5db9f9c3809d84c67d23b75a4d8eae8c2aec16990b6118d5ab0b661071d90773</originalsourceid><addsrcrecordid>eNqVkF1rFDEUhoModq2Cv0AGb_RmbLKZfF0uS-tWKhVRb0MmOdNmmZmMScbivzfDblEKIl7lkPPkOTkvQi8JfkewIGebHVZ4LdQjtCJNo2qpmuYxWmHCeM2ElCfoWUp7jIlikj9FJ-XklBK-Qpeb6jP88HBXha76FMMUkulTlUO57kIcqnwLpbyZe5N9GBdqG4aphwHGbOLP6iM4b_0I6Tl60pWn8OJ4nqKvF-dftrv66vr95XZzVVsmeK475lrVKUslVk42lgu3pq1gpnESDEi7NmAJVwq3nBDpmGlLxZc1ncJC0FP05uCdYvg-Q8p68MlC35sRwpy0oJRywpkq5OsH5D7McSyf00RRJThbL9DbA2RjSClCp6foh7KZJlgvU_V9uAV9dfTN7QDuN3hMswDfDkAcfNY29D3YJbW0NznpBCbaW-3HJdfSD_FGu-C1adMyazFoD72ZjCacNJxQTgXjDZNFvPtDXIgu_1X3T9WH_1fdNx7KfgEB2sIv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>193976529</pqid></control><display><type>article</type><title>A Review of Proposals to Reform the Regulation of Complementary Medicines</title><source>MEDLINE</source><source>CSIRO Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Harvey, Ken J</creator><creatorcontrib>Harvey, Ken J</creatorcontrib><description>In 2003, the Therapeutic Goods Administration instituted a major recall of products made by Pan Pharmaceuticals Limited. Later that year, an expert committee produced 49 recommendations for complementary medicines reform, many of which were to be implemented by the proposed Australia New Zealand Therapeutic Products Authority (ANZTPA). In 2008, the Pan Pharmaceuticals affair reached some conclusion in the courts, the ANZTPA had been abandoned and the case for reform had intensified. There was widespread and increasing use of complementary medicines yet consumers were often unaware that, unlike conventional medicines, these medicines were not evaluated for efficacy. The justification of this two-tiered regulatory system was that complementary medicines are relatively low-risk products. However low risk does not mean no risk. A number of consumers have been shown to use these products for conditions where there is no evidence of effect, potentially placing them at risk. In addition, promotion often overstates their benefits while minimising and sometimes denying known adverse effects and drug interactions. Complaint procedures are overloaded and the 'sanctions' available do not deter repeat offenders. A number of regulatory reforms have been suggested to overcome these problems; they are reviewed in this paper.</description><identifier>ISSN: 0156-5788</identifier><identifier>EISSN: 1449-8944</identifier><identifier>DOI: 10.1071/AH090279</identifier><identifier>PMID: 19563316</identifier><language>eng</language><publisher>Australia: CSIRO</publisher><subject>Advertising ; Alternative medicine ; Australia ; Complementary Therapies - legislation &amp; jurisprudence ; Complementary Therapies - standards ; Consumers ; Generic products ; Government Regulation ; Habitual offenders ; Health administration ; Health Care Reform - legislation &amp; jurisprudence ; Market entry ; Medical laws and legislation ; Medical personnel ; Medicine ; New Zealand ; Pharmaceutical industry ; Pharmaceuticals ; Pharmacists ; Prescription drugs ; Product recalls ; Regulation ; Regulatory reform ; Sanctions ; Studies ; Therapeutic Goods Administration (Australia)</subject><ispartof>Australian health review, 2009-05, Vol.33 (2), p.279-287</ispartof><rights>Copyright Australian Healthcare and Hospitals Association May 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c576t-f5db9f9c3809d84c67d23b75a4d8eae8c2aec16990b6118d5ab0b661071d90773</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3350,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19563316$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harvey, Ken J</creatorcontrib><title>A Review of Proposals to Reform the Regulation of Complementary Medicines</title><title>Australian health review</title><addtitle>Aust Health Rev</addtitle><description>In 2003, the Therapeutic Goods Administration instituted a major recall of products made by Pan Pharmaceuticals Limited. Later that year, an expert committee produced 49 recommendations for complementary medicines reform, many of which were to be implemented by the proposed Australia New Zealand Therapeutic Products Authority (ANZTPA). In 2008, the Pan Pharmaceuticals affair reached some conclusion in the courts, the ANZTPA had been abandoned and the case for reform had intensified. There was widespread and increasing use of complementary medicines yet consumers were often unaware that, unlike conventional medicines, these medicines were not evaluated for efficacy. The justification of this two-tiered regulatory system was that complementary medicines are relatively low-risk products. However low risk does not mean no risk. A number of consumers have been shown to use these products for conditions where there is no evidence of effect, potentially placing them at risk. In addition, promotion often overstates their benefits while minimising and sometimes denying known adverse effects and drug interactions. Complaint procedures are overloaded and the 'sanctions' available do not deter repeat offenders. A number of regulatory reforms have been suggested to overcome these problems; they are reviewed in this paper.</description><subject>Advertising</subject><subject>Alternative medicine</subject><subject>Australia</subject><subject>Complementary Therapies - legislation &amp; jurisprudence</subject><subject>Complementary Therapies - standards</subject><subject>Consumers</subject><subject>Generic products</subject><subject>Government Regulation</subject><subject>Habitual offenders</subject><subject>Health administration</subject><subject>Health Care Reform - legislation &amp; jurisprudence</subject><subject>Market entry</subject><subject>Medical laws and legislation</subject><subject>Medical personnel</subject><subject>Medicine</subject><subject>New Zealand</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceuticals</subject><subject>Pharmacists</subject><subject>Prescription drugs</subject><subject>Product recalls</subject><subject>Regulation</subject><subject>Regulatory reform</subject><subject>Sanctions</subject><subject>Studies</subject><subject>Therapeutic Goods Administration (Australia)</subject><issn>0156-5788</issn><issn>1449-8944</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqVkF1rFDEUhoModq2Cv0AGb_RmbLKZfF0uS-tWKhVRb0MmOdNmmZmMScbivzfDblEKIl7lkPPkOTkvQi8JfkewIGebHVZ4LdQjtCJNo2qpmuYxWmHCeM2ElCfoWUp7jIlikj9FJ-XklBK-Qpeb6jP88HBXha76FMMUkulTlUO57kIcqnwLpbyZe5N9GBdqG4aphwHGbOLP6iM4b_0I6Tl60pWn8OJ4nqKvF-dftrv66vr95XZzVVsmeK475lrVKUslVk42lgu3pq1gpnESDEi7NmAJVwq3nBDpmGlLxZc1ncJC0FP05uCdYvg-Q8p68MlC35sRwpy0oJRywpkq5OsH5D7McSyf00RRJThbL9DbA2RjSClCp6foh7KZJlgvU_V9uAV9dfTN7QDuN3hMswDfDkAcfNY29D3YJbW0NznpBCbaW-3HJdfSD_FGu-C1adMyazFoD72ZjCacNJxQTgXjDZNFvPtDXIgu_1X3T9WH_1fdNx7KfgEB2sIv</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>Harvey, Ken J</creator><general>CSIRO</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RO</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>8AI</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AXJJW</scope><scope>AYAGU</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FREBS</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20090501</creationdate><title>A Review of Proposals to Reform the Regulation of Complementary Medicines</title><author>Harvey, Ken J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c576t-f5db9f9c3809d84c67d23b75a4d8eae8c2aec16990b6118d5ab0b661071d90773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Advertising</topic><topic>Alternative medicine</topic><topic>Australia</topic><topic>Complementary Therapies - legislation &amp; jurisprudence</topic><topic>Complementary Therapies - standards</topic><topic>Consumers</topic><topic>Generic products</topic><topic>Government Regulation</topic><topic>Habitual offenders</topic><topic>Health administration</topic><topic>Health Care Reform - legislation &amp; jurisprudence</topic><topic>Market entry</topic><topic>Medical laws and legislation</topic><topic>Medical personnel</topic><topic>Medicine</topic><topic>New Zealand</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceuticals</topic><topic>Pharmacists</topic><topic>Prescription drugs</topic><topic>Product recalls</topic><topic>Regulation</topic><topic>Regulatory reform</topic><topic>Sanctions</topic><topic>Studies</topic><topic>Therapeutic Goods Administration (Australia)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harvey, Ken J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Asian Business Database</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Access via ABI/INFORM (ProQuest)</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Asian Business Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Asian &amp; European Business Collection</collection><collection>Australia &amp; New Zealand Database</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Asian &amp; European Business Collection (Alumni)</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Australian health review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harvey, Ken J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Review of Proposals to Reform the Regulation of Complementary Medicines</atitle><jtitle>Australian health review</jtitle><addtitle>Aust Health Rev</addtitle><date>2009-05-01</date><risdate>2009</risdate><volume>33</volume><issue>2</issue><spage>279</spage><epage>287</epage><pages>279-287</pages><issn>0156-5788</issn><eissn>1449-8944</eissn><abstract>In 2003, the Therapeutic Goods Administration instituted a major recall of products made by Pan Pharmaceuticals Limited. Later that year, an expert committee produced 49 recommendations for complementary medicines reform, many of which were to be implemented by the proposed Australia New Zealand Therapeutic Products Authority (ANZTPA). In 2008, the Pan Pharmaceuticals affair reached some conclusion in the courts, the ANZTPA had been abandoned and the case for reform had intensified. There was widespread and increasing use of complementary medicines yet consumers were often unaware that, unlike conventional medicines, these medicines were not evaluated for efficacy. The justification of this two-tiered regulatory system was that complementary medicines are relatively low-risk products. However low risk does not mean no risk. A number of consumers have been shown to use these products for conditions where there is no evidence of effect, potentially placing them at risk. In addition, promotion often overstates their benefits while minimising and sometimes denying known adverse effects and drug interactions. Complaint procedures are overloaded and the 'sanctions' available do not deter repeat offenders. A number of regulatory reforms have been suggested to overcome these problems; they are reviewed in this paper.</abstract><cop>Australia</cop><pub>CSIRO</pub><pmid>19563316</pmid><doi>10.1071/AH090279</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0156-5788
ispartof Australian health review, 2009-05, Vol.33 (2), p.279-287
issn 0156-5788
1449-8944
language eng
recordid cdi_pubmed_primary_19563316
source MEDLINE; CSIRO Journals; EZB-FREE-00999 freely available EZB journals
subjects Advertising
Alternative medicine
Australia
Complementary Therapies - legislation & jurisprudence
Complementary Therapies - standards
Consumers
Generic products
Government Regulation
Habitual offenders
Health administration
Health Care Reform - legislation & jurisprudence
Market entry
Medical laws and legislation
Medical personnel
Medicine
New Zealand
Pharmaceutical industry
Pharmaceuticals
Pharmacists
Prescription drugs
Product recalls
Regulation
Regulatory reform
Sanctions
Studies
Therapeutic Goods Administration (Australia)
title A Review of Proposals to Reform the Regulation of Complementary Medicines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A11%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Review%20of%20Proposals%20to%20Reform%20the%20Regulation%20of%20Complementary%20Medicines&rft.jtitle=Australian%20health%20review&rft.au=Harvey,%20Ken%20J&rft.date=2009-05-01&rft.volume=33&rft.issue=2&rft.spage=279&rft.epage=287&rft.pages=279-287&rft.issn=0156-5788&rft.eissn=1449-8944&rft_id=info:doi/10.1071/AH090279&rft_dat=%3Cproquest_pubme%3E733361659%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=193976529&rft_id=info:pmid/19563316&rft_informt_id=10.3316/ielapa.161461363756458&rfr_iscdi=true